Any attempt to punish communications about pharmaceuticals in the absence of proof of falsity, intent, actual deception and injury not only would be inconsistent with the existing interpretation of the Consumer Fraud Act, but also would be barred by the First Amendment.
PRODUCTS LIABILITY & TOXIC TORTS
Pharmaceutical Marketing and The N.J. Consumer Fraud Act
New Jersey Law Journal
December 14, 2012
This article requires premium access
This article requires premium access to The New Jersey Law Journal. Please sign in or subscribe to read the full text.